NL-OMON36826已完成不适用
[11C]Erlotinib pharmacokinetics: an in vivo study using positron emission tomography in non-small cell lung cancer patients with and without erlotinib therapy. - [11C]erlotinib kinetics in NSCLC with and without erlotinib
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients with NSCLC, planned to receive erlotinib for therapy will be included in this study.
- •Patients age: between 18 and 70 years
- •Life expectancy of at least 12 weeks
- •Malignant lesion of at least 1.5 cm diameter within the chest as measured by CT
- •Performance status Karnofsky index >60%
- •Written informed consent
排除标准
- •Claustrophobia
- •Pregnant or lactating patients
- •Metal implants in the thorax (e.g. pacemakers), interfering with PET/CT imaging
- •Concurrent treatment with experimental drugs
研究者
相似试验
尚未招募
不适用
[11C]Erlotinib in non-small cell lung cancer patients with and without erlotinib therapy.on-small cell lung cancer NSCLCNiet-kleincellig longkankerNL-OMON28948VU University Medical Center10
已完成
不适用
Efficacy and pharmacokinetics study of erlotinib in patients with non-small cell lung cancerAdvanced non-small cell lung cancerJPRN-UMIN000012862Shizuoka cancer center70
招募中
不适用
In-vivo Bioequivalence Test of Erlotinib tablets with brand drug (TARCEVA® 150 mg, Rosche, Switzerland)IRCT20200105046010N46Actero Pharma. Co.24
招募中
不适用
Imaging of [11C]erlotinib pharmacokinetics in non small cell lung cancer patients; an in vivo study with positron emission tomography10038666lung cancerNL-OMON32923Vrije Universiteit Medisch Centrum10
招募中
不适用
In-vivo Bioequivalence Test of Erlotinib tablets with brand drug (TARCEVA® 150 mg, Rosche, Switzerland)Bio equivalence test.IRCT20200105046010N51Abidi Pharmaceutical Company24